Table 5.
Relationship of patient and treatment factors to the risk of diagnostic mammograms and ipsilateral invasive procedures after index DCIS excision in multivariable analyses*
| Factor | Risk of diagnostic mammograms |
Risk of ipsilateral invasive procedures |
||
| HR (95% CI) | Overall P | HR (95% CI) | Overall P | |
| Age at diagnosis, y | .49 | .004 | ||
| 25–49 | 1.00 (referent) | 1.00 (referent) | ||
| 50–59 | 0.92 (0.74 to 1.14) | 0.94 (0.81 to 1.10) | ||
| 60–69 | 0.87 (0.67 to 1.13) | 0.92 (0.76 to 1.10) | ||
| 70–84 | 0.80 (0.60 to 1.07) | 0.73 (0.60 to 0.90)† | ||
| Diagnosis year | .005 | .006 | ||
| 1990–1991 | 1.00 (referent) | 1.00 (referent) | ||
| 1992–1993 | 0.84 (0.64 to 1.11) | 1.09 (0.89 to 1.34) | ||
| 1994–1995 | 0.75 (0.58 to 0.98)‡ | 1.22 (1.01 to 1.48)‡ | ||
| 1996–1997 | 0.83 (0.64 to 1.07) | 1.28 (1.06 to 1.55)† | ||
| 1998–1999 | 1.15 (0.88 to 1.49) | 1.12 (0.92 to 1.36) | ||
| 2000–2001 | 0.95 (0.72 to 1.25) | 0.97 (0.79 to 1.18) | ||
| Race | .72 | .20 | ||
| White | 1.00 (referent) | 1.00 (referent) | ||
| Asian | 0.96 (0.77 to 1.18) | 1.02 (0.88 to 1.18) | ||
| Black | 0.98 (0.78 to 1.24) | 1.16 (1.00 to 1.36) | ||
| Hispanic | 1.06 (0.84 to 1.34) | 0.92 (0.77 to1.10) | ||
| Other | 0.61 (0.28 to 1.31) | 0.84 (0.55 to 1.26) | ||
| BMI at diagnosis, kg/m2 | .43 | .10 | ||
| <25 (normal) | 1.00 (referent) | 1.00 (referent) | ||
| 25–29 (overweight) | 1.01 (0.86 to 1.19) | 0.96 (0.86 to 1.08) | ||
| ≥30 (obese) | 1.11 (0.94 to 1.30) | 0.88 (0.78 to 0.99)‡ | ||
| Menopausal status at diagnosis | .89 | .49 | ||
| Postmenopausal | 1.00 (referent) | 1.00 (referent) | ||
| Pre/perimenopausal | 1.05 (0.84 to 1.32) | 1.05(0.90 to 1.23) | ||
| Diabetes at diagnosis | .65 | .24 | ||
| No | 1.00 (referent) | 1.00 (referent) | ||
| Yes | 1.02 (0.79 to 1.32) | 0.90 (0.74 to 1.09) | ||
| Family history of breast cancer at diagnosis | .59 | .08 | ||
| No | 1.00 (referent) | 1.00 (referent) | ||
| Yes | 1.07 (0.91 to 1.27) | 1.13 (1.00 to 1.27) | ||
| Menopausal hormone therapy use at diagnosis | .03 | .33 | ||
| None | 1.00 (referent) | 1.00 (referent) | ||
| Former Use | 1.24 (1.03 to 1.48)‡ | 1.03 (0.91 to 1.17) | ||
| Current Use | 1.32 (1.08 to 1.60)† | 1.13 (0.99 to 1.30) | ||
| Treatment of DCIS | .08 | .04 | ||
| BCS alone | 1.00 (referent) | 1.00 (referent) | ||
| BCS/tamoxifen | 0.87 (0.59 to 1.29) | 0.96 (0.74 to 1.25) | ||
| BCS/radiation | 1.19 (1.02 to 1.38)‡ | 1.15 (1.04 to 1.28)† | ||
| BCS/radiation/tamoxifen | 1.16 (0.91 to 1.47) | 1.05 (0.88 to 1.26) | ||
*
Analyses adjusted for diagnosis year; age, race, body mass index, menopausal status, diabetes, family history, menopausal hormone therapy use (all at the time of diagnosis); treatment of DCIS, year of follow-up and site. BCS = breast-conserving surgery; BMI = body mass index; CI = confidence interval; DCIS = ductal carcinoma in situ; HR = hazard ratio. All statistical tests were two-sided.
†
P < .01.
‡
P < .05.